Bone and metal targeted polymeric nanoparticles (US20150125391 A1): a patent evaluation

References

• Schroeder A, Heller DA, Winslow MM, et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer. 2012;12:39–50.
   Web of Science ®Google Scholar
• Mundy GR. Metastasis: metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584–593.
   PubMed Web of Science ®Google Scholar
• Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11:411–425.
   PubMed Web of Science ®Google Scholar
• Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 2008;14:2519–2526.
   PubMed Web of Science ®Google Scholar
• Narayanan D, Anitha A, Jayakumar R, et al. In vitro and in vivo evaluation of osteoporosis therapeutic peptide PTH 1-34 loaded PEGylated chitosan nanoparticles. Mol Pharm. 2013;10:4159–4167.
   PubMed Web of Science ®Google Scholar
• Duchi S, Sotgiu G, Lucarelli E, et al. Mesenchymal stem cells as delivery vehicle of porphyrin loaded nanoparticles: effective photoinduced in vitro killing of osteosarcoma. J Control Release. 2013;168:225–237.
   PubMed Web of Science ®Google Scholar
• Siris ES, Lyles KW, Singer FR, et al. Medical management of Paget’s disease of bone: indications for treatment and review of current therapies. J Bone Miner Res. 2006;21:94–98.
   Web of Science ®Google Scholar
• Trajkovski B, Petersen A, Strube P, et al. Intra-operatively customized implant coating strategies for local and controlled drug delivery to bone. Adv Drug Deliv Rev. 2012;64:1142–1151.
   PubMed Web of Science ®Google Scholar
• Song YY, Schmidt-Stein F, Bauer S, et al. Amphiphilic TiO2 nanotube arrays: an actively controllable drug delivery system. J Am Chem Soc. 2009;131:4230–4232.
   PubMed Web of Science ®Google Scholar
• Gultepe E, Nagesha D, Sridhar S, et al. Nanoporous inorganic membranes or coatings for sustained drug delivery in implantable devices. Adv Drug Deliv Rev. 2010;62:305–315.
   PubMed Web of Science ®Google Scholar
• Wang D, Miller SC, Kopečková P, et al. Bone-targeting macromolecular therapeutics. Adv Drug Deliv Rev. 2005;57:1049–1076.
   PubMed Web of Science ®Google Scholar
• Thamake SI, Raut SL, Gryczynski Z, et al. Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. Biomaterials. 2012;33:7164–7173.
   PubMed Web of Science ®Google Scholar
• Iafisco M, Margiotta N. Silica xerogels and hydroxyapatite nanocrystals for the local delivery of platinum–bisphosphonate complexes in the treatment of bone tumors: a mini-review. J Inorg Biochem. 2012;117:237–247.
   PubMed Web of Science ®Google Scholar
• Wang D, Miller SC, Shlyakhtenko LS, et al. Osteotropic peptide that differentiates functional domains of the skeleton. Bioconjug Chem. 2007;18:1375–1378.
   PubMed Web of Science ®Google Scholar
• Zhang G, Guo B, Wu H, et al. A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med. 2012;18:307–314.
   PubMed Web of Science ®Google Scholar
• Liang C, Guo B, Wu H, et al. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nat Med. 2015;21:288–294.
   PubMed Web of Science ®Google Scholar
• Swami A, Basto P, Karp J, et al. Bone and metal targeted polymeric nanoparticles. US20150125391 A1. 2014.
   Google Scholar
• Swami A, Reagan MR, Basto P, et al. Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci USA. 2014;111:10287–10292.
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 2005;5:21–28.
   PubMed Web of Science ®Google Scholar
• Suva LJ, Washam C, Nicholas RW, et al. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 2011;7:208–218.
   PubMed Web of Science ®Google Scholar
• Chang J, Wang Z, Tang E, et al. Inhibition of osteoblastic bone formation by nuclear factor-κB. Nat Med. 2009;15:682–689.
   PubMed Web of Science ®Google Scholar
• Yip KH, Feng H, Pavlos NJ, et al. p62 ubiquitin binding-associated domain mediated the receptor activator of nuclear factor-κB ligand-induced osteoclast formation: a new insight into the pathogenesis of Paget’s disease of bone. Am J Pathol. 2006;169:503–514.
   PubMed Web of Science ®Google Scholar
• Miller K, Erez R, Segal E, et al. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew Chem Int Edit. 2009;48:2949–2954.
   PubMed Web of Science ®Google Scholar
• Morton SW, Shah NJ, Quadir MA, et al. Osteotropic therapy via targeted layer-by-layer nanoparticles. Adv Healthc Mater. 2014;3:867–875.
   PubMed Web of Science ®Google Scholar
• Wang X, Yang Y, Jia H, et al. Peptide decoration of nanovehicles to achieve active targeting and pathology-responsive cellular uptake for bone metastasis chemotherapy. Biomater Sci. 2014;2:961–971.
   PubMed Web of Science ®Google Scholar
• Zitzmann S, Ehemann V, Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res. 2002;62:5139–5143.
   PubMed Web of Science ®Google Scholar
• Sykes EA, Chen J, Zheng G, et al. Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. ACS Nano. 2014;8:5696–5706.
   PubMed Web of Science ®Google Scholar
• Schipper ML, Iyer G, Koh AL, et al. Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small. 2009;5:126–134.
   PubMed Web of Science ®Google Scholar
• He C, Hu Y, Yin L, et al. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31:3657–3666.
   PubMed Web of Science ®Google Scholar
• Nagae M, Hiraga T, Yoneda T. Acidic microenvironment created by osteoclasts causes bone pain associated with tumor colonization. J Bone Miner Metab. 2007;25:99–104.
   PubMed Web of Science ®Google Scholar
• Tezuka KI, Tezuka Y, Maejima A, et al. Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J Biol Chem. 1994;269:1106–1109.
   PubMed Web of Science ®Google Scholar
• Brömme D, Okamoto K, Wang BB, et al. Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts functional expression of human cathepsin O2 in spodoptera frugiperda and characterization of the enzyme. J Biol Chem. 1996;271:2126–2132.
   PubMed Web of Science ®Google Scholar
• Song XR, Wang X, Yu SX, et al. Co9Se8 nanoplates as a new theranostic platform for photoacoustic/magnetic resonance dual-modal-imaging-guided chemo-photothermal combination therapy. Adv Mater. 2015;27:3285–3291.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang J, Wang Y, et al. Multi-responsive photothermal-chemotherapy with drug-loaded melanin-like nanoparticles for synergetic tumor ablation. Biomaterials. 2016;81:114–124.
   PubMed Web of Science ®Google Scholar
• Son SJ, Reichel J, He B, et al. Magnetic nanotubes for magnetic-field-assisted bioseparation, biointeraction, and drug delivery. J Am Chem Soc. 2005;127:7316–7317.
   PubMed Web of Science ®Google Scholar
• Thomas CR, Ferris DP, Lee JH, et al. Noninvasive remote-controlled release of drug molecules in vitro using magnetic actuation of mechanized nanoparticles. J Am Chem Soc. 2010;132:10623–10625.
   PubMed Web of Science ®Google Scholar
• Huebsch N, Kearney CJ, Zhao X, et al. Ultrasound-triggered disruption and self-healing of reversibly cross-linked hydrogels for drug delivery and enhanced chemotherapy. Proc Natl Acad Sci USA. 2014;111:9762–9767.
   PubMed Web of Science ®Google Scholar
• Nejadnik MR, Yang X, Bongio M, et al. Self-healing hybrid nanocomposites consisting of bisphosphonated hyaluronan and calcium phosphate nanoparticles. Biomaterials. 2014;35:6918–6929.
   PubMed Web of Science ®Google Scholar
• Alghamdi HS, Bosco R, Both SK, et al. Synergistic effects of bisphosphonate and calcium phosphate nanoparticles on peri-implant bone responses in osteoporotic rats. Biomaterials. 2014;35:5482–5490.
   PubMed Web of Science ®Google Scholar
• Lee GY, Qian WP, Wang L, et al. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano. 2013;7:2078–2089.
   PubMed Web of Science ®Google Scholar
• Wu X, Sun X, Guo Z, et al. In vivo and in situ tracking cancer chemotherapy by highly photostable NIR fluorescent theranostic prodrug. J Am Chem Soc. 2014;136:3579–3588.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Kwok RTK, Tang BZ, et al. Targeted theranostic platinum (IV) prodrug with a built-in aggregation-induced emission light-up apoptosis sensor for noninvasive early evaluation of its therapeutic responses in situ. J Am Chem Soc. 2014;136:2546–2554.
   PubMed Web of Science ®Google Scholar
• Kircher MF, De La Zerda A, Jokerst JV, et al. A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat Med. 2012;18:829–834.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Al Zaki A, Hui JZ, et al. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science. 2012;338:903–910.
   PubMed Web of Science ®Google Scholar